A NEW treatment for men [...].
A four-year study by GlaxoSmithKline (GSK) into a combined treatment using two drugs found results were better than using the individual drugs - Avodart or Tamsulosin -alone.
Almost half of men over 50 have the condition benign prostate hyperplasia (BPH), an enlarged prostate, which in itself is not life-threatening, but can lead to complications and the need for surgery.
BPH is associated with incontinence and the urge to urinate more frequently and can impair quality of life. In the GSK study, some men with moderate-to-severe symptoms were given the dual treatment CombAT, while others received just Avodart or Tamsulosin. After four years, those who had the combined treatment reported fewer symptoms than those on single doses.
Dr Mark Embleton, Urology Consultant at the University College of London, said: "As a treating clinician, the CombAT study results are very encouraging as they show that BPH can be effectively treated using combination therapy, reducing the risk of disease progression and surgery related to this disease. "Disease progression often leads to more severe symptoms and can cause AUR, a sudden inability to pass urine, which is always painful and involves treatment with catherisation or prostate surgery."
|Printer friendly Cite/link Email Feedback|
|Publication:||Evening Chronicle (Newcastle, England)|
|Date:||Oct 19, 2009|
|Previous Article:||A TOP German cancer specialist [...].|
|Next Article:||Health workers at head of vaccine queue.|
|Animal activists draw ire of milk industry.|
|Over 800 urologists to attend Malaysia meet.|